Prostate Cancer – knowing what to do is complicated
Over 1 in 7 men will be diagnosed with prostate cancer at some point in their lifetime. Despite this only 1 in 15 of these men will die from prostate cancer, and 98.9% of patients will survive over 5 years1. Most men with prostate cancer die with rather than of the disease. The graphic on the left2 shows the impact that prostate cancer screening has on diagnosis.
These disparities can be attributed to a number of factors, including race, PSA screening, lifestyle habits, and access to healthcare. PSA screening has caused an increase in prostate cancer diagnosis, due to the low specificity of PSA as a prostate cancer marker3. This has led to many men being over diagnosed and overtreated. Being able to distinguish indolent prostate cancer from aggressive more serious disease is the key issue facing clinicians today.
Active surveillance has shown to be an effective management technique for low-risk prostate cancer, with up to 100% cancer-free survival after 10 years4. Earlier diagnosis of aggressive prostate cancer will also help patients receive the most appropriate course of treatment for them. OCProDx is the only test that measures biological features of the actual prostate tumour. By measuring and tracking the tumours potential to extend outside of the prostate, disease progression can be tracked independent of the need for biopsy.
Sources of Information
- National Cancer Institute – SEER Program
- U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 2012.
- “The Problem With Prostate Screening”, Richard J. Ablin, New York Times, Nov 25 2014
- Preston, Mark A., et al. “Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.” Urologic Oncology: Seminars and Original Investigations. Vol. 33. No. 9. Elsevier, 2015.